Oluyemi Okupe Sells 3,975 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 3,975 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $19.98, for a total value of $79,420.50. Following the sale, the chief financial officer directly owned 318,789 shares in the company, valued at $6,369,404.22. This represents a 1.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.

Hims & Hers Health Trading Down 0.7%

Shares of NYSE:HIMS opened at $19.37 on Thursday. The company has a market capitalization of $4.42 billion, a P/E ratio of 37.98, a P/E/G ratio of 2.31 and a beta of 2.32. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The business’s 50 day simple moving average is $20.08 and its 200 day simple moving average is $33.91.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.11 earnings per share. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quent Capital LLC bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Bogart Wealth LLC lifted its stake in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health in the 1st quarter valued at $30,000. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on HIMS shares. Needham & Company LLC raised Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Monday, March 9th. Citigroup raised Hims & Hers Health from a “sell” rating to a “neutral” rating and raised their target price for the company from $13.25 to $24.00 in a report on Tuesday, March 10th. Bank of America raised Hims & Hers Health from an “underperform” rating to a “neutral” rating and raised their target price for the company from $12.50 to $23.00 in a report on Tuesday, March 10th. Truist Financial reaffirmed a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Finally, BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $31.71.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Renewed/expanded Novo Nordisk tie‑up and new membership program broaden access to FDA‑approved GLP‑1s (including Wegovy) and add a recurring‑revenue product tier — a clear revenue and distribution positive for HIMS’ prescription business. Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership – Has The Bull Case Changed?
• Positive Sentiment: Platform expansion (labs, hormone therapy, broader weight programs) aims to lift ARPU and customer LTV, supporting medium‑term growth if HIMS converts GLP‑1 demand into subscription and prescription margins. Hims & Hers Advances a Consumer-Centric Digital Health Platform
• Neutral Sentiment: CFO disclosed a small, pre‑arranged 10b5‑1 sale (3,975 shares) — repeats recent pattern of planned sales; not an unusual governance flag but increases short‑term supply. Insider Sale Filing (SEC)
• Neutral Sentiment: Price action has been volatile (recent intraday dips and heavy volume vs. averages) — reflects mixed headlines rather than a single fundamental shift. HIMS Stock Dips: Key Facts
• Negative Sentiment: Bank of America cut its 2026 price target (to $21) and warns HIMS will face near‑term margin pressure as it pivots from compounded GLP‑1s to higher‑cost branded therapies — analyst multiple compression and earnings risks weigh on sentiment. Hims & Hers price target slashed amid GLP-1 transition
• Negative Sentiment: Shareholder law firm launched an investigation alleging potential disclosure issues — introduces legal and regulatory overhang that can pressure the stock until resolved. Schall Law Firm Investigation
• Negative Sentiment: HIMS disclosed a social‑engineering incident at a third‑party customer service platform with limited data exposure — reputational and compliance risk that could raise remediation costs and regulatory scrutiny. Hims & Hers says limited data stolen in social engineering attack

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.